Creatine supplementation in Huntington's disease: A placebo-controlled pilot trial

Neurology

Volumn 61, Issue 7, 2003, Pages 925-930

  Verbessem, P ^a   Lemiere, J ^a   Eijnde, B O ^a   Swinnen, S ^a   Vanhees, L ^a,b   Van Leemputte, M ^a   Hespel, Peter ^a,b   Dom, R ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Fac of Phys Educ and Physiother   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; PLACEBO;

ADULT; ARTICLE; BICYCLE ERGOMETER; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COORDINATION; DOUBLE BLIND PROCEDURE; DYNAMOMETRY; ELBOW FLEXION; EXERCISE TEST; FEMALE; FLEXOR MUSCLE; HUMAN; HUNTINGTON CHOREA; ISOKINETIC EXERCISE; MALE; MOTOR PERFORMANCE; NEUROMUSCULAR DISEASE; NEUROMUSCULAR FUNCTION; PRIORITY JOURNAL; RATING SCALE;

EID: 0141959170     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000090629.40891.4B     Document Type: Article

References (30)

1. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev 2000;80:1107-1213.
2. Persky AM, Brazeau GA. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev 2001;53:161-176.
3. Andreassen OA, Dedeoglu A, Ferrante RJ, et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 2001;8:479-491.
4. Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000;20:4389-4397.
5. Matthews RT, Yang L, Jenkins BG, et al. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci 1998;18:156-163.
6. Shear DA, Haik KL, Dunbar GL. Creatine reduces 3- nitropropionic-acid-induced cognitive and motor abnormalities in rats. Neuroreport 2000;11:1833-1837.
7. Juhn MS, Tarnopolsky M. Oral creatine supplementation and athletic performance: a critical review. Clin J Sport Med 1998;8:286-297.
8. Terjung RL, Clarkson P, Eichner ER, et al. American College of Sports Medicine roundtable. The physiological and health effects of oral creatine supplementation. Med Sci Sports Exerc 2000;32:706-717.
9. Hagenfeldt L, von Dobeln U, Solders G, Kaijser L. Creatine treatment in MELAS. Muscle Nerve 1994;17:1236-1237.
10. Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999;52:854-857.
11. Vorgerd M, Grehl T, Jager M, et al. Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial. Arch Neurol 2000;57:956-963.
12. Harris RC, Söderlund K, Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin Sci 1992;83:367-374.
13. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997;41:160-165.
14. Lodi R, Schapira AH, Manners D, et al. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 2000;48:72-76.
15. Vandenberghe K, Goris M, Van Hecke P, Van Leemputte M, Vangerven L, Hespel P. Long-term creatine intake is beneficial to muscle performance during resistance training. J Appl Physiol 1997;83:2055-2063.
16. Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979;29:1-3.
17. Bergmeyer HU. Methods of enzymatic analysis. Weinheim: VCH Verslagsgesellschaft, 1985.
18. Huntington Study Group. Unified Huntington's Disease Rating Scale. Reliability and consistency. Mov Disord 1996;11:136-142.
19. Swinnen SP, Verschueren SMP, Bogaerts H, Dounskaia N, Lee TD, Stelmach GE. Age-related deficits in motor learning and differences in feedback processing during the production of a bimanual coordination pattern. Cogn Neuropsychol 1998;15:439-466.
20. Van Leemputte M, Vandenberghe K, Hespel P. Shortening of muscle relaxation time after creatine loading. J Appl Physiol 1999;86:840-844.
21. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology 2000;54:452-458.
22. Feigin A, Kieburtz K, Bordwell K, et al. Functional decline in Huntington's disease. Mov Disord 1995;10:211-214.
23. Bachoud-Levi AC, Maison P, Bartolomeo P, et al. Retest effects and cognitive decline in longitudinal follow-up of patients with early HD. Neurology 2001;56:1052-1058.
24. Snowden J, Craufurd D, Griffiths H, Thompson J, Neary D. Longitudinal evaluation of cognitive disorder in Huntington's disease. J Int Neuropsychol Soc 2001;7:33-44.
25. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999;5:347-350.
26. Mazzini L, Balzarini C, Colombo R, et al. Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results. J Neurol Sci 2001;191:139-144.
27. Groeneveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003;53:437-445.
28. Dechent P, Pouwels PJ, Wilken B, et al. Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. Am J Physiol 1999;277(Pt 2):R698-R704.
29. Hespel P, Eijnde BO, Van Leemputte M, et al. Oral creatine supplementation facilitates the rehabilitation of disuse atrophy and alters the expression of muscle myogenic factors in humans. J Physiol 2001;536(Pt 2):625-633.
30. Op 't Eijnde B, Urso B, Richter EA, Greenhaff PL, Hespel P. Effect of oral creatine supplementation on human muscle GLUT4 protein content after immobilization. Diabetes 2001;50:18-23.